Thyroid Gland Involvement and the Efficiency of Thyroidectomy in Patients Having Larynx and Hypopharyngeal Cancers Treated with Surgery

Azadeh Nasehi 1, Hojjat Allah Abbaszadeh 1, Navid Ahmady Roozbahany 2, Maryam Sadat Khoramgah 3, Foozhan Tahmasebinia 4, Ali Asghar Payvandi 1, * and Shahrokh Khoshsirat 1, **

1 Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Dalla Lana school of Public Health, University of Toronto, Toronto, Canada
3 Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, Iran

* Corresponding author: Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: aliasgharpayvandi@gmail.com
** Corresponding author: Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: dr_khoshsirat@yahoo.com

Received 2019 January 05; Revised 2019 July 29; Accepted 2019 July 31.

Abstract

Background: Thyroid gland involvement and invasion during larynx and hypopharynx cancers is rare, but due to the anatomical closeness of the thyroid gland and the larynx, it could occur through local invasion. Thyroidectomy is usually performed in patients with thyroid gland involvement having larynx and hypopharyngeal cancers. A lot of controversies exist regarding the thyroid gland involvement and efficiency of a different kind of thyroidectomy intraoperatively in these types of cancers.

Objectives: Thus, elucidating the exact role of thyroidectomy, its efficiency, and parameters associated with thyroid gland involvement is critical in treating the patients with the larynx and hypopharyngeal cancers.

Methods: In this retrospective study, the medical records of 117 patients admitted to Loghman Hakim Hospital from 2001 to 2015 with laryngeal and hypopharyngeal carcinoma, who underwent laryngectomy with or without thyroidectomy as a primary treatment of cancer, were evaluated. Several parameters, including gender, prevalence, location of the thyroid gland and lymph node involvement, the exact type of malignancy, differentiation stage of the tumor cells, the exact method of thyroidectomy, thyroid function, and its post-surgical cancer recurrence were assessed.

Results: The prevalence of laryngeal cancers was significantly higher in males than females and most of the malignancies were squamous cell carcinoma (SCC). The location of the malignancy was mostly at supraglottis, glottis, transglottis, and subglottis, respectively. The rate of thyroid gland involvement was approximately 11.96%. Lobectomy was performed in 57.14 %, total thyroidectomy was performed in 35.71 %, and in 7.14% of the patients, thyroidectomy was not performed. After the initial surgery, out of 11.96% of all patients with thyroid gland involvement, 28.5% had a recurrence of the thyroid gland. Only 21% of the patients with thyroid gland involvement had hypothyroidism after the surgery.

Conclusions: The rate of thyroid gland involvement in the pathology report after surgery was approximately 3.41% of the thyroid gland involvement, which is low. We concluded that thyroidectomy is a very efficient way, but it should be limited to cases of subglottic or transglottic involvement or in cases of bilateral tumors, high staging, post-cricoid involvement, and clear radiological evidence or in the event of muscle involvement.

Keywords: Larynx, Cancer, Epidemiology, Thyroid Involvement

1. Background

Larynx cancers are the most common malignancies that are diagnosed in the head and neck. Their incidence rate is so much higher in men than women (1). Timely diagnosis, correct staging, and the right choice of treatment for each individual patient are required for having the successful treatment of the disease. If larynx cancer is treated at an early stage, more than 90% of the patients will live without any symptoms of the disease for up to 5 years. At present, surgical treatment plays a vital role in the treatment of invasive tumors. Although hypopharyngeal cancer is rare, it has a generally poor prognosis and it has one of the most challenging head and neck surgery cases. Supraglottic and subglottic cancers have a difficult prognosis (2–4). The thyroid gland and larynx are anatom-
2. Objectives

Considering the above-mentioned information, an appropriate sample size of the study for evaluating the incidence of thyroid gland involvement in different types of larynx and hypopharynx cancers, the efficiency of thyroidectomy and the impact of thyroid involvement on the rate of relapse and survival of patients seems necessary.

3. Methods

This study was performed extensively and reviewed by written medical records of 117 patients admitted with the larynx and/or hypopharyngeal cancer diagnosis in the ear, nose and throat (ENT) and Head and Neck Surgery Department of Loghman Hakim Hospital from 2001 to 2015. Our target population underwent laryngectomy with or without thyroidectomy as a primary treatment of cancer. After considering several parameters, including gender, prevalence, location of the thyroid gland and lymph node involvement, the exact type of malignancy, differentiation stage of the tumor cells, the exact method of thyroidectomy, thyroid function, and its post-surgical cancer recurrence, 117 patients were chosen based on the available data. The informed consent form for using clinical information in their files has been completed by all patients. The required information is extracted from the patient’s clinical records. The information that was analyzed include age, gender, onset and duration of symptoms, clinical stage, location of involvement, grade, preoperative thyroid function, clinical examination results of larynx, thyroid and neck, surgical type, type of thyroidectomy, surgical complications, radiotherapy, postoperative results of thyroid and parathyroid biochemistry tests, smoking history, and overall disease-free and disease-related survival. Patient tracking duration was at least 5 years.

3.1. Statistical Analysis

Statistical tests were performed, using SPSS for Windows software and the results were evaluated for their meaningfulness. For qualitative variables, the Chi-square test was used and for quantitative variables, the t-test was performed.

4. Results

The results of this study showed that in our study, the prevalence of laryngeal cancers was significantly higher in males (92.31%) than females (7.69%) (Figure 1A). The mean age of the disease was 58.47 years. The level of involvement in the anatomical regions of the larynx was the highest in the supraglottic area with 34.19%, the glottic involvement was 26.50%, the transglottic was 23.93%, and the subglottic area was 15.38% of the patients (Figure 1B).

TNM STAGING examined the extent of the tumor and the rate of lymph node involvement and metastasis. It
showed that T2 was 27.35%, T3 61.54%, and T4a 11.12% (Figure 1C).

In assessing the rate of lymph node involvement, out of 117 examined patients, 74.35% had no lymph nodes involvement, while this rate was 16.23% in the N1 stage of involvement, 8.54% in N2a patients, and less than 1% in N2b patients (Figure 1D).

Regarding thyroid gland involvement in laryngeal carcinoma in 117 patients, 11.96% of them had thyroid gland involvement (Figure 2C).

The study of surgical procedures utilized in the treatment of patients with laryngeal carcinoma demonstrated the number of supraglottic surgery procedures in 3 patients, the verticular procedure in 3 subjects, and the total method in 111 patients (Table 1).

Regarding the staging of patients, who have been diagnosed with laryngeal carcinoma, out of 117 patients, 23.1% were in stage 2, 60.7% in stage 3, 13.7% in stage 4a, and 2.6% in stage 4b (Table 2).

According to the results, the rate of differentiation in cancer cells based on pathologic findings was 20.5% poorly differentiated, 63% distinct, and 16.5% distinct differentiated (Figure 2A).

The major risk factors for thyroid gland involvement in larynx cancers are laryngeal cartilage involvement, extensive subglottic, and transglottic involvement. By comparing thyroid gland involvement in the patients with laryngeal carcinoma in stages 2 and 3, 43% of them had thyroid gland involvement and the thyroid gland involvement in stage 4a was 67% and in stage 4b, thyroid gland involvement was 88%, which is significantly higher than those in patients in stages 4a, 2, and 3 (Figure 2B).

A comparison of thyroid gland function before and after surgery showed that 21% of the patients with thyroid gland involvement had hypothyroidism after the surgery (Table 3).

By comparing the relationship between the relapse rates of the tumor with thyroid involvement after the initial surgery, 88.04% of all patients had no thyroid involvement; among them, 1.94% cases had recurrence while out
Table 1. The Surgical Methods Used in the Treatment of Patients with Laryngeal Carcinoma

| Method       | Frequency | Percent | Valid Percent | Cumulative Percent |
|--------------|-----------|---------|---------------|--------------------|
| Supra-glottic| 3         | 2.6     | 2.6           | 2.6                |
| Vertical     | 3         | 2.6     | 2.6           | 5.2                |
| Total        | III       | 94.9    | 94.9          | 100                |
| Total        | 117       | 100     | 100           | 100                |

*aThe supraglottic method was performed in 3 patients, vertical in 3, and total in 117.

Table 2. Staging of 117 Patients, Who Have Been Diagnosed with Laryngeal Carcinoma

| Stage   | Frequency | Percent | Valid Percent | Cumulative Percent |
|---------|-----------|---------|---------------|--------------------|
| Stage 2 | 27        | 23.1    | 23.1          | 23.1               |
| Stage 3 | 71        | 60.7    | 60.7          | 83.8               |
| Stage 4a| 16        | 13.7    | 13.7          | 97.5               |
| Stage 4b| 3         | 2.6     | 2.6           | 100                |
| Total   | 117       | 100     | 100           | 100                |

*aIt was shown that 27 patients were in stage 2, 71 in stage 3, 16 in stage 4a, and 3 in stage 4b.

Figure 2. A. Shows the degree of lymph node involvement based on TNM; B, the extent of cancer cell differentiation based on pathologic findings. According to the results, 24 cases were poorly differentiated, 74 cases were distinct, and 19 cases were distinctly differentiated; C, the rate of thyroid gland involvement in the laryngeal carcinoma, 88.04% had no thyroid involvement, while 11.96% of them had thyroid gland involvement; D, comparison of thyroid gland involvement with laryngeal carcinoma. Patients in stages 2 and 3 had a progression of the disease to 43% of gland involvement and 57% of them had no thyroid gland involvement; we had 67% thyroid gland involvement in stage 4a, while 33% of them had no involvement of thyroid. In stage 4b, thyroid gland involvement was 88% and in 12% of them, thyroid gland involvement was not present.

In the study of thyroid gland involvement in patients undergoing surgery and subsequent radiotherapy, out of 88.03% of patients, who did not have thyroid gland involvement, 58.25% of the patients did not have radiotherapy, but 41.75% of them had, and out of all patients, who had thyroid involvement, 50% of them had no radiotherapy, and 50% of the cases had radiotherapy (Figure 3B).
5. Discussion

The results of this study showed that the prevalence of laryngeal cancers was significantly higher in males than females and the highest decades of age for the patients were in men, who were mostly in their sixth decade and in women who were mostly in their fifth decade. A comparison of the extent of involvement in different anatomical regions of the larynx showed that the highest level of involvement was in the supraglottic region, which is 34.19%. The involvement of the glottic was seen in 26.50% of the patients, 23.93% of the transglottic region, and 15.38% in the subglottic area. Previous studies suggested a greater involvement in the supraglottic region, which was consistent with our results (14, 15). In a study, glote had a higher level of involvement (16). Only 16.5% of cancer cells were distinctly differentiated and the degree of differentiation could be a critical factor in the thyroid gland invasion in laryngeal carcinoma.

Regarding thyroid gland involvement in laryngeal carcinoma in all patients, it was shown that 11.96% of them had thyroid gland involvement (Figure 2A). Extensive subglottic and transglottic involvement are the major risk factors for thyroid gland involvement in larynx cancers.

Thyroidectomy was performed during laryngeal carcinoma with lobectomy or total thyroidectomy and in 7.14% of cases, no thyroidectomy was performed. The researchers concluded that routine thyroid resection in larynx cancers should be limited to cases of subglottic or transglottic involvement (3). They recommended thyroidectomy in cases of bilateral tumors, high staging, post-cricoid involvement, and clear radiological evidence (5) or in the event of muscle involvement or in case of subglottic involvement of more than 10 mm (7).

5.1. Conclusions

The prevalence of laryngeal cancers was significantly higher in males than females; this type of cancer is more common in men because far fewer women than men use tobacco. Based on our findings, the rate of thyroid gland involvement in the pathology report after surgery was approximately 3.41% of the thyroid gland involvement, which is low. We concluded that thyroidectomy is a very efficient way, but it should be limited to cases of subglottic or transglottic involvement or in cases of bilateral tumors, high staging, post-cricoid involvement, and clear radiological evidence or in the event of muscle involvement.

Acknowledgments

We are thankful for the funding provided by Hearing Disorder Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Footnotes

Authors’ Contribution: All authors contributed equally to this work.

Conflict of Interests: There is no conflict of interest between the authors.

Ethical Consideration: This study has been approved by the Ethics Committee of Cancer Research Center of Shahid Beheshti University of Medical Sciences.

Patient Consent: The informed consent form for using clinical information of the patients has been signed by all patients.

References

1. Mangussi-Gomes J, Danelon-Leonhardt F, Moussalem GF, Ahumada NG, Oliveira CL, Hojaij FC. Thyroid gland invasion in advanced squamous cell carcinoma of the larynx and hypopharynx. Braz J Otorhinolaryngol. 2017;83(3):269–75. doi: 10.1016/j.bjorl.2016.03.019. [PubMed: 27209377].

2. Arslanoglu S, Eren E, Ozkul Y, Ciger E, Kopar A, Onal K, et al. Management of thyroid gland invasion in laryngeal and hypopharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2016;273(2):511–5. doi: 10.1007/s00405-015-3828-x. [PubMed: 26547312].

3. Mourad M, Saman M, Sawhney R, Ducic Y. Management of the thyroid gland during total laryngectomy in patients with laryngeal squamous cell carcinoma. Laryngoscope. 2015;125(8):1835–8. doi: 10.1002/lary.25263. [PubMed: 26059344].

4. Chang JW, Koh YW, Chung WY, Hong SW, Choi EC. Predictors of thyroid gland involvement in hypopharyngeal squamous cell carcinoma. Yonsei Med J. 2015;56(3):812–8. doi: 10.3349/ymj.2015.56.3.812. [PubMed: 26537090]. [PubMed Central: PMC4397454].

5. Gad Z, Mohamed A, Fakhri I. When would we advocate a total thyroidectomy in cases of hypopharyngeal carcinoma? J Egypt Natl Canc Inst. 2014;26(2):93–8. doi: 10.1016/j.jnci.2014.01.002. [PubMed: 24841640].

6. Joshi P, Nair S, Chaturvedi P, Nair D, Shivakumar T, D’Cruz AK. Thyroid gland involvement in carcinoma of the hypopharynx. J Laryngol Otol. 2014;128(1):64–7. doi: 10.1017/S0022215113001277. [PubMed: 24429057].

7. Nayak SP, Singh V, Dam A, Bhowmik A, Jadhav TS, Ashraf M, et al. Mechanism of thyroid gland invasion in laryngeal cancer and indications for thyroidectomy. Indian J Otolaryngol Head Neck Surg. 2013;65(Suppl 1):69–73. doi: 10.1007/s12070-012-0530-9. [PubMed: 24427889]. [PubMed Central: PMC379592].

8. Kim JW, Han GS, Byun SS, Lee DP, Cho BH, Kim YM. Management of thyroid gland invasion in laryngopharyngeal cancer. Auris Nasus Larynx. 2008;35(2):209–12. doi: 10.1016/j.anl.2007.07.003. [PubMed: 17850001].

9. Hilly O, Razi R, Vaisbuch Y, Strenov K, Koren R, et al. Thyroid gland involvement in advanced laryngeal cancer: association with clinical and pathologic characteristics. Head Neck. 2012;34(11):1586–90. doi: 10.1002/hed.21972. [PubMed: 2280299].

10. Elliott MS, Odell EW, Tysome JR, Connor SE, Jeannon JP, et al. Role of thyroidectomy in advanced laryngeal and pharyngolaryngeal carcinoma. Otolaryngol Head Neck Surg. 2010;142(3):385–5. doi: 10.1016/j.otohns.2010.02.006. [PubMed: 20493357].

11. Sefati N, Abbasszadeh HA, Fadai Fathabady F, Abdollahifar MA, Khorramghah MS, Darabi S, et al. The combined effects of mesenchymal stem cell conditioned media and low-level laser on stereological and biomechanical parameter in hypothyroidism rat model. J Lasers Med Sci. 2018;9(4):243–8. doi: 10.15171/jlms.2018.44. [PubMed: 31119018]. [PubMed Central: PMC6499561].

12. Clark OH, Levin K, Zeng QH, Greenspan FS, Siperstein A. Thyroid cancer: the case for total thyroidectomy. Eur J Cancer Clin Oncol. 1988;24(2):305–13. doi: 10.1016/0277-5379(88)90273-8. [PubMed: 3281846].

13. Schroder DM, Chambors A, France CJ. Operative strategy for thyroid cancer. Is total thyroidectomy worth the price? Cancer. 1986;58(10):2320–8. doi: 10.1002/1097-0142(19861015)58:10<2320::aid-cncr2820581027>3.0.co;2-u. [PubMed: 3756777].

14. Lo Galbo AM, de Bree R, Kuik DJ, Lips PT, Mary B, Von Blomberg E, et al. The prevalence of hypothyroidism after treatment for laryngeal and hypopharyngeal carcinomas: Are autoantibodies of influence? Acta Otolaryngol. 2007;127(3):312–7. doi: 10.1080/00016480600818096. [PubMed: 17364370].

15. Garcia-Serra A, Amdur RJ, Morris CG, Mazzaferri E, Mendenhall WM. Thyroid function should be monitored following radiotherapy to the low neck. Am J Clin Oncol. 2005;28(3):255–8. doi: 10.1097/01.coc.0000145985.64440.ac. [PubMed: 15923797].

16. Sinard RJ, Tobin EJ, Mazzaferri EL, Hodgson SE, Young DC, Kunz AJ, et al. Hypothyroidism after treatment for nonthyroid head and neck cancer. Arch Otolaryngol Head Neck Surg. 2000;126(5):652–7. doi: 10.1001/archotol.126.5.652. [PubMed: 10807335].

Int J Cancer Manag. 2019;12(10):e88750.